Navigation Links
Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
Date:9/24/2007

's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affecting Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating requirements; general changes in International and U.S. generally accepted accounting principles; growth in costs and expenses; and the impact of acquisitions, divestitures and other unusual items. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Form 20-F for the fiscal year ended December 31, 2006, filed with the SEC on March 5 2007, Amarin's statutory annual report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC on May 9, 2007 and in its Reports of Foreign Issuer on Form 6-K furnished to the SEC.


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Dallas, TX, USA (PRWEB) , ... July 30, ... ... nano and microsystems, has appointed Francois Vieillard as Sales & Marketing Director. ... executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ business development activities ...
(Date:7/30/2015)... , July 30, 2015 According ... Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity ... Development, Preclinical, Clinical Trial), by End Users - Global ... is expected to reach USD 2,107.99 million by 2020 ... of 15.29%. Browse more than ...
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... globe, ISN improves the efficiency and effectiveness of contractor management systems. ISN,s online contractor ... in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Dallas, TX , ISN has additional offices in Calgary , ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... , INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, ... it has priced a $300 million securitization transaction intended ... royalties. , Upon closing of the transaction, which is ... will sell to QHP Royalty Sub LLC ("QHP"), a ...
... , MINNEAPOLIS, Oct. 28 Techne Corporation,s (Nasdaq: ... September 30, 2009 decreased 6.4% to $26.8 million or ... $.74 per diluted share for the quarter ended September ... mainly due to foreign currency fluctuations, decreased consolidated net ...
... ... of work in September, health care industry continued growing, adding 19,000 new jobs. But ... ... healthcare and related fields continued to grow, even as more Americans found themselves out of ...
Cached Biology Technology:PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 2Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 3Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 4Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 5Techne Corporation Releases Unaudited First Quarter Results For Fiscal Year 2010 6The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 2The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 3The MedZilla Report for September 2009 - Care Grows Again in September and - Surprisingly - Pharma Sales Jobs Up Too 4
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... MA -- Using ultrasound waves, MIT engineers have found ... drugs, making transdermal drug delivery more efficient. This technology ... needle-free vaccinations, according to the researchers. "This could ... cortisol, for example systemic drugs and proteins such ...
... strides in identifying genes that lead to an increased ... a continuum of social deficits, communication difficulties and cognitive ... these genetic risk factors impact the brain,s structure and ... developed. This led researchers at UCLA ...
... FARMINGTON, Conn., Sept. 13, 2012 /PRNewswire-iReach/ -- Global ... time offer on personalized medicine, next generation sequencing ... Pacific, a bio/pharmaceutical and life sciences industry analyst ... http://photos.prnewswire.com/prnh/20120913/CG74123 ) Personalized Medicine: Companies, Trends ...
Cached Biology News:Getting (drugs) under your skin 2Getting (drugs) under your skin 3Study reveals how common gene mutation affects kids with autism spectrum disorders 2Study reveals how common gene mutation affects kids with autism spectrum disorders 3How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 2How to Differentiate Your Pharmaceutical Product in the Personalized Medicine Segment 3